Pneumococcal 15-Valent Conjugate Vaccine Approved for Pediatric Use
For children, Vaxneuvance is administered as a 4-dose series at 2, 4, 6 and 12 through 15 months of age (and at least 2 months after the 3rd dose).
For children, Vaxneuvance is administered as a 4-dose series at 2, 4, 6 and 12 through 15 months of age (and at least 2 months after the 3rd dose).
Children with physical disabilities, neurologic and neurodevelopmental disorders, and autism are at higher risk for vaccine-preventable illnesses.
Priorix is administered as a 2-dose series (each dose is approximately 0.5mL) via subcutaneous injection.
The trial included 1678 children who received a third dose of the 3µg formulation at least 2 months after the second dose of a 2-dose series at a time when Omicron was the predominant variant.
The Pfizer-BioNTech COVID-19 vaccine can be administered as a single booster dose to individuals 5 to 11 years of age at least 5 months after completion of the primary series.
The KidCOVE study included children 6 months to less than 6 years of age who received either two 25mcg doses of mRNA-1273 or placebo, separated by 28 days.
As the medical field shifted its priorities to treating COVID-19 at the start of the pandemic, routine immunization was one of the many medical fields to experience disruption. What was the scope of this disruption and what are possible ways to address it?
CDC updates hepatitis B vaccination recommendation for adults
The Emergency Use Authorization was based on safety and immunogenicity data provided to the Agency.
The KidCOVE study is currently evaluating the immunogenicity, safety, and tolerability of the mRNA-1273 vaccine in healthy children.